Carlsquare Equity Research has published a research update following the Q2 2023 report.
I dag offentliggjorde Midsummer sin delårsrapport för det andra kvartalet 2023.
Revenue back on track, better margins from the next quarter Programme end-of-life announcement for H...
Movinn announced on August 14th, that the company (as operator and tenant) has signed a long-term le...
Margin pressure to persist but fade in coming quarters We cut EBITA by 16%, 8%, and 7% for '23e-'25e...
Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which ca...
Redeye comments on the wholesale distributor agreement in the US with VHSS.
Q2 adj. EBITDA 6% above our estimates New '23 guidance, EUR 125-130m top line & 47-50% margin Share ...
Redeye comments on GiG’s Q2-results which came in above expectations driven by strong profitability ...
Raute reports Q2 results on Aug 25. We see Q2 a bit soft but growth is set to continue next year wit...
Taaleri reported Q2 EBIT of EUR 17.8m, coming clearly above Refinitiv consensus at EUR 8.
Netcompany has today released its Q2 2023 interim report, which at first glance looks slightly disap...
Redeye retains its positive view despite lowering its forecasts and Base Case.
Redeye is encouraged to see a stabilisation in Sleep Cycle’s total number of subscribers, thanks to ...
Redeye updates on EG7 post its Q2-results which came in close to our expectations.
Arcede Pharma räknar med att slutföra den sista toxikologistudien i augusti 2023 och har aviserat om...
Redeye lowers its sales estimates on all time horizons for Sedana Medical following the Q2 report, r...
Fortsatt leverans från bolaget Omsättningen i kvartalet uppgick till 30,2 mkr, vilket motsvarar en t...
Redye comments on Alelion’s Q2 report, which was largely in line with our expectations.
Redeye comments on Physitracks’s Q2-results, wherein the reported figures generally align with our e...
